Table 4.

Therapeutic effects of DX and NAA in B6D2F₁ mice bearing P388/0 and P388/DX tumors

Tumor	Dosage, mg/kg		Median survival time, days ± SEM*	% increase in life span
	DX	NAA
P388/0	0	0	7.58  ± 0.32	0
	0.5		17.3  ± 0.80	+128
	1.0		19.1  ± 0.87	+152
	2.0		21.1  ± 0.66	+178
		70	7.75  ± 0.65	+2
	0.5	70	18.5  ± 0.65‡	+144
	1.0	70	20.8  ± 1.14§	+174
	2.0	70	21.9  ± 1.02¶	+189
P388/DX	0		7.55  ± 0.38	0
	0.5		11.3  ± 0.91	+49
	1.0		13.3  ± 0.76	+75
	2.0		15.6  ± 0.54	+106
		70	7.55  ± 0.67	+0
	0.5	70	12.8  ± 0.86‡	+69
	1.0	70	15.2  ± 0.55‡	+101
	2.0	70	19.0  ± 0.82†	+151

Male B6D2F₁ mice were inoculated with tumor cells, 10⁶/mouse, i.p. on day 0, and treated by DX and/or NAA starting on day 1, daily for 4 days per week for 2 weeks. There were five mice per dosage and 10 mice in the control group. 

^*Survival time was recorded at the time of death with the following decimal values: 8 a.m. (0.0), 1 p.m. (0.25), and 5 p.m. (0.5). Comparing the median-survival time for treatment with DX for the same tumor in the presence and absence of NAA: †, P < 0.005; ‡, P < 0.01; §, P < 0.05; ¶, not significant.